Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.

Jose F. Leis, Steven L. Primack, Susan E. Schubach, Peter T. Curtin, Brian J. Druker, Richard T. Maziarz

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Pulmonary leukostasis is a rare but serious and often fatal complication of chronic myeloid leukemia (CML) in blast crisis and acute myeloid leukemia. Treatment options are limited for these patients. Imatinib mesylate (STI-571, Gleevec, Novartis) is a potent and selective inhibitor of the BCR-abl tyrosine kinase, the molecular abnormality that causes CML. The case of a 74-year-old man with a history of CML who presented in myeloid blast crisis with pulmonary leukostasis characterized by increasing dyspnea, hypoxemia, fever, and impending respiratory failure is reported. The patient was treated with single agent imatinib mesylate (IM) with rapid decrease in his white blood cell count (WBC) and marked improvement in his respiratory status. No electrolyte abnormalities consistent with tumor lysis syndrome were observed. IM may be an effective single agent therapy for pulmonary leukostasis in patients with CML blast crisis who are at the risk for tumor lysis.

Original languageEnglish (US)
Pages (from-to)ECR30
JournalHaematologica
Volume89
Issue number9
StatePublished - Sep 2004

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.'. Together they form a unique fingerprint.

  • Cite this